HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
QGEN
Qiagen N.V.
QGEN's fundamentals are strong: it turned 21% of its revenue into free cash flow and its operating margin rose 2 points to 25%. At 26x earnings, it's trading in line with its usual 27x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
QGEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QGEN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
QGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 20x | $50.10 | — |
| Cheap | 21x | $41.00 | -18% |
| Fair | 26x | $51.64 | +3.1% |
| Current | 26x | $50.10 | — |
| Expensive | 99x | $194 | +287% |
Historical ranges are pointers, not guarantees.
QGEN's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
QGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
QGEN has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
QGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.54 | +30% |
| Q2 2026 | $1.95 | +15% |
| Q1 2026 | $1.89 | +340% |
| Q4 2025 | $1.97 | +418% |
| Q3 2025 | $1.86 | +354% |
| Q2 2025 | $1.70 | +431% |
| Q1 2025 | $0.43 | -72% |
| Q4 2024 | $0.38 | -75% |
| Q3 2024 | $0.41 | -72% |
QGEN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over QGEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
QGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $535M | +0.3% |
| Q1 2026 | $492.3M | +1.8% |
| Q4 2025 | $540.4M | +3.7% |
| Q3 2025 | $532.6M | +6.1% |
| Q2 2025 | $533.5M | +7.5% |
| Q1 2025 | $483.5M | +5.4% |
| Q4 2024 | $521.2M | +2.4% |
| Q3 2024 | $501.9M | +5.5% |
QGEN's revenue has grown year over year for nine quarters in a row: $535M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +1.9 points |
| Q1 2026 | 24% | -0.2 points |
| Q4 2025 | 28% | +5.6 points |
| Q3 2025 | 24% | +1.9 points |
| Q2 2025 | 23% | +69 points |
| Q1 2025 | 24% | +3.2 points |
| Q4 2024 | 23% | +1.1 points |
| Q3 2024 | 22% | +1.9 points |
QGEN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over QGEN on cash flow, with more consistent year-over-year improvement.
QGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $157.8M | +31% |
| Q1 2026 | $53.7M | -44% |
| Q4 2025 | $117.2M | -17% |
| Q3 2025 | $119M | -14% |
| Q2 2025 | $120.6M | -5.6% |
| Q1 2025 | $95.8M | +1.2% |
| Q4 2024 | $141.9M | +43% |
| Q3 2024 | $138M | +65% |
QGEN generated $448M in free cash flow over the past year, down 9.8% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over QGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
QGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -1.1M shares |
| 1 year | -4.7% | -10.4M shares |
| 3 years | -7.1% | -15.8M shares |
| 5 years | -10% | -24.1M shares |
| Available history | -8.3% | -18.7M shares |
QGEN has 208M diluted shares, down 4.7% from a year ago, with $509M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $496.7M |
| Q4 2025 | $2.7M |
| Q3 2025 | $9.3M |
| Q2 2025 | $10.3M |
| Q1 2025 | $280.1M |
| Q4 2024 | $906,000 |
| Q3 2024 | $6.2M |
QGEN spent $509M buying back its own shares over the past year, up 71% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over QGEN on leverage, with a lower net debt burden relative to earnings.
QGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.0x | Very low |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.6x | Moderate |
| Q3 2024 | 2.6x | Moderate |
QGEN's net debt is about 1.2 years of its operating earnings (EBITDA), up from a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
QGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.4 | Overbought |
| Stochastic | 92.8 | Overbought |
QGEN's weekly RSI is 71 (overbought) and its Stochastic is 93 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
QGEN PE vs Healthcare Sector
| Metric | QGEN | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.6% below |
| PE % | 44 | 29 | 15 pts above |
QGEN is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
QGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.7 | 5.1% above |
| 20 week MA | $44.4 | 13% above |
| 50 week MA | $43.5 | 15% above |
| 100 week MA | $44.1 | 14% above |
| 200 week MA | $43.9 | 14% above |
QGEN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
QGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $52.6 | +55% |
| 2021 | $52.6 | $55.7 | +5.8% |
| 2022 | $55.7 | $49.7 | -11% |
| 2023 | $49.7 | $43.8 | -12% |
| 2024 | $43.8 | $44.0 | +0.5% |
| 2025 | $44.0 | $47.8 | +8.6% |
| 2026 YTD | $47.8 | $50.1 | +4.9% |
QGEN has the edge over HIMS on returns for 2026, with the stronger performance.